AU2011326164B2 - Fusion proteins comprising an engineered knottin peptide and uses thereof - Google Patents

Fusion proteins comprising an engineered knottin peptide and uses thereof Download PDF

Info

Publication number
AU2011326164B2
AU2011326164B2 AU2011326164A AU2011326164A AU2011326164B2 AU 2011326164 B2 AU2011326164 B2 AU 2011326164B2 AU 2011326164 A AU2011326164 A AU 2011326164A AU 2011326164 A AU2011326164 A AU 2011326164A AU 2011326164 B2 AU2011326164 B2 AU 2011326164B2
Authority
AU
Australia
Prior art keywords
receptor
binding
knottin
integrin
eeti
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011326164A
Other languages
English (en)
Other versions
AU2011326164A1 (en
Inventor
Jennifer R. Cochran
Douglas S. Jones
Mihalis S. Kariolis
Ping-Chuan Tsai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of AU2011326164A1 publication Critical patent/AU2011326164A1/en
Application granted granted Critical
Publication of AU2011326164B2 publication Critical patent/AU2011326164B2/en
Priority to AU2016210712A priority Critical patent/AU2016210712B2/en
Priority to AU2018200587A priority patent/AU2018200587B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43518—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from spiders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Insects & Arthropods (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2011326164A 2010-11-08 2011-11-07 Fusion proteins comprising an engineered knottin peptide and uses thereof Ceased AU2011326164B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2016210712A AU2016210712B2 (en) 2010-11-08 2016-08-04 Fusion proteins comprising an engineered knottin peptide and uses thereof
AU2018200587A AU2018200587B2 (en) 2010-11-08 2018-01-24 Fusion proteins comprising an engineered knottin peptide and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41135010P 2010-11-08 2010-11-08
US61/411,350 2010-11-08
PCT/US2011/059599 WO2012064658A1 (en) 2010-11-08 2011-11-07 Fusion proteins comprising an engineered knottin peptide and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2016210712A Division AU2016210712B2 (en) 2010-11-08 2016-08-04 Fusion proteins comprising an engineered knottin peptide and uses thereof

Publications (2)

Publication Number Publication Date
AU2011326164A1 AU2011326164A1 (en) 2013-05-30
AU2011326164B2 true AU2011326164B2 (en) 2016-05-05

Family

ID=46051256

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2011326164A Ceased AU2011326164B2 (en) 2010-11-08 2011-11-07 Fusion proteins comprising an engineered knottin peptide and uses thereof
AU2016210712A Ceased AU2016210712B2 (en) 2010-11-08 2016-08-04 Fusion proteins comprising an engineered knottin peptide and uses thereof
AU2018200587A Ceased AU2018200587B2 (en) 2010-11-08 2018-01-24 Fusion proteins comprising an engineered knottin peptide and uses thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2016210712A Ceased AU2016210712B2 (en) 2010-11-08 2016-08-04 Fusion proteins comprising an engineered knottin peptide and uses thereof
AU2018200587A Ceased AU2018200587B2 (en) 2010-11-08 2018-01-24 Fusion proteins comprising an engineered knottin peptide and uses thereof

Country Status (7)

Country Link
US (3) US10844106B2 (enExample)
EP (2) EP3604549A1 (enExample)
JP (2) JP6170435B2 (enExample)
AU (3) AU2011326164B2 (enExample)
CA (1) CA2817197C (enExample)
DK (1) DK2638173T3 (enExample)
WO (1) WO2012064658A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008045252A2 (en) * 2006-10-04 2008-04-17 The Board Of Trustees Of The Leland Stanford Junior University Engineered integrin binding peptides
JP6170435B2 (ja) * 2010-11-08 2017-07-26 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 改変ノッチンペプチドを含む融合タンパク質及びその使用
WO2013078250A2 (en) 2011-11-22 2013-05-30 The Board Of Trustees Of The Leland Stanford Junior University Cystine knot peptides that bind alpha-v-beta-6 integrin
WO2013177187A2 (en) 2012-05-22 2013-11-28 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
US9587001B2 (en) 2012-10-19 2017-03-07 The Board Of Trustees Of The Leland Stanford Junior University Conjugated knottin mini-proteins containing non-natural amino acids
SG11201504602VA (en) 2012-12-10 2015-07-30 Hutchinson Fred Cancer Res Lipocalin fusion partners
AU2013359179B2 (en) * 2012-12-14 2017-10-05 Aravive Biologics, Inc. Modified AXL peptides and their use in inhibition of AXL signaling in anti-metastatic therapy
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
US10166273B2 (en) * 2014-08-12 2019-01-01 The Board Of Trustees Of The Leland Stanford Junior University Synergistic tumor treatment with antibodies targeting PD-1, PD-L1 or CTLA4 and integrin-binding-Fc-fusion protein
WO2016025645A1 (en) 2014-08-12 2016-02-18 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker
CN107847554A (zh) * 2015-06-26 2018-03-27 弗莱德哈钦森癌症研究中心 治疗性肽及其使用方法
CN108135970B (zh) 2015-09-09 2023-09-01 弗莱德哈钦森癌症中心 软骨归巢肽
TWI799366B (zh) * 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺
GB2562933B (en) * 2016-01-08 2022-06-29 Maxion Therapeutics Ltd Binding members with altered diversity scaffold domains
WO2017139570A1 (en) * 2016-02-12 2017-08-17 Massachusetts Intitute Of Technology Synergistic tumor treatment with il-2, an integrin-binding-fc fusion protein, and a cancer vaccinne
US10765625B2 (en) 2016-03-15 2020-09-08 The Board Of Trustees Of The Leland Stanford Junior University Knottin-drug conjugates and methods of using the same
WO2018044234A1 (en) * 2016-08-31 2018-03-08 Nanyang Technological University Cysteine-rich polypeptides and conjugates and methods of using the same
US10350266B2 (en) 2017-01-10 2019-07-16 Nodus Therapeutics, Inc. Method of treating cancer with a multiple integrin binding Fc fusion protein
WO2018132516A1 (en) 2017-01-10 2018-07-19 Nodus Therapeutics Combination tumor treatment with an integrin-binding-fc fusion protein and immune modulator
JP7191025B2 (ja) 2017-01-18 2022-12-16 フレッド ハッチンソン キャンサー センター Ｔｅａｄ相互作用を妨害するためのペプチド組成物およびその使用方法
AU2018236465A1 (en) 2017-03-16 2019-08-22 Blaze Bioscience, Inc. Cartilage-homing peptide conjugates and methods of use thereof
CA3064436A1 (en) 2017-06-15 2018-12-20 Blaze Bioscience, Inc. Renal-homing peptide conjugates and methods of use thereof
GB201711208D0 (en) 2017-07-12 2017-08-23 Iontas Ltd Ion channel inhibitors
AU2018307752A1 (en) * 2017-07-24 2020-03-12 Rutgers, The State University Of New Jersey Phosphatidylserine targeting fusion molecules and methods for their use
WO2019126240A1 (en) 2017-12-19 2019-06-27 Blaze Bioscience, Inc. Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof
US11235032B2 (en) 2019-01-23 2022-02-01 Massachusetts Institute Of Technology Combination immunotherapy dosing regimen for immune checkpoint blockade
JP2022527351A (ja) * 2019-04-02 2022-06-01 イーライ リリー アンド カンパニー 結合ペプチドを選択し検出するための方法
CN113645989A (zh) * 2019-04-29 2021-11-12 斯坦福大学托管董事会 使用工程化的肝细胞生长因子二聚体片段进行眼部治疗的方法
WO2020237078A1 (en) * 2019-05-22 2020-11-26 The Board Of Trustees Of The Leland Stanford Junior University Drug conjugates and methods of using same
KR20220071225A (ko) * 2019-09-30 2022-05-31 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 노틴-면역자극제 접합체 및 관련 조성물 및 방법
WO2022026906A2 (en) * 2020-07-30 2022-02-03 The Board Of Trustees Of The Leland Stanford Junior University Lysosomal targeting molecules comprising knottin peptides and related compositions and methods
MX2020012914A (es) * 2020-11-27 2022-05-30 Centro De Investig Cientifica Y De Educacion Superior De Ensenada Baja California Cicese Proteina andamio para la generacion de proteinas quimericas de union a antigeno.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000044898A2 (en) * 1999-01-29 2000-08-03 Amgen Inc. Novel agouti and agouti-related peptide analogs
WO2002034906A2 (de) * 2000-10-26 2002-05-02 Georg-August-Universität Göttingen Verfahren zur exposition von peptiden und polypeptiden auf der zelloberfläche von bakterien
WO2008045252A2 (en) * 2006-10-04 2008-04-17 The Board Of Trustees Of The Leland Stanford Junior University Engineered integrin binding peptides

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468634A (en) 1991-06-24 1995-11-21 The University Of North Carolina At Chapel Hill Axl oncogene
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
WO2002061055A2 (en) 2001-01-31 2002-08-08 Mount Sinai Hospital Methods for regulating the kinase domain of ephb2
GB0110430D0 (en) 2001-04-27 2001-06-20 Medical Res Council Protein variants and uses thereof
AU2005205412B2 (en) * 2004-01-20 2011-08-11 Merus N.V. Mixtures of binding proteins
CA2577329A1 (en) * 2004-08-16 2006-03-02 Medimmune, Inc. Eph receptor fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity
WO2007100358A2 (en) 2005-10-07 2007-09-07 University Of Chicago Convergent synthesis of proteins by kinetically controlled ligation
US7666622B2 (en) * 2005-10-19 2010-02-23 Regeneron Pharmaceuticals, Inc. Monomeric self-associating fusion polypeptides and therapeutic uses thereof
EP1958957A1 (en) 2007-02-16 2008-08-20 NascaCell Technologies AG Polypeptide comprising a knottin protein moiety
EP2170395A1 (en) * 2007-07-02 2010-04-07 Wyeth LLC Modulators of axl for use in treating bone disorders
KR20100058509A (ko) 2007-07-31 2010-06-03 메디뮨 엘엘씨 다중특이적 에피토프 결합 단백질 및 이의 용도
EP2195028A2 (en) * 2007-09-18 2010-06-16 The Jackson Laboratory Antibodies and fc fusion protein modifications with enhanced persistence or pharmacokinetic stability in vivo and methods of use thereof
US8906356B2 (en) * 2007-11-05 2014-12-09 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
EP2349327A4 (en) 2008-10-23 2012-11-28 Massachusetts Inst Technology COMMITMENT DIRECTED FC RECEIVERS ACTIVATORS
US8329826B2 (en) 2008-11-06 2012-12-11 The Board Of Trustees Of The Leland Stanford Junior University Surface modification of interpenetrating polymer networks
US8778888B2 (en) * 2009-11-06 2014-07-15 The Board Of Trustees Of The Leland Stanford Junior University Cystine knot peptides binding to alpha IIb beta 3 integrins and methods of use
RU2556822C2 (ru) 2010-01-22 2015-07-20 Те Борд Оф Трастиз Оф Те Лилэнд Стэнфорд Джуниор Юниверсити Ингибирование axl сигнализации в антиметастатической терапии
JP6170435B2 (ja) * 2010-11-08 2017-07-26 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 改変ノッチンペプチドを含む融合タンパク質及びその使用
US10350266B2 (en) * 2017-01-10 2019-07-16 Nodus Therapeutics, Inc. Method of treating cancer with a multiple integrin binding Fc fusion protein

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000044898A2 (en) * 1999-01-29 2000-08-03 Amgen Inc. Novel agouti and agouti-related peptide analogs
WO2002034906A2 (de) * 2000-10-26 2002-05-02 Georg-August-Universität Göttingen Verfahren zur exposition von peptiden und polypeptiden auf der zelloberfläche von bakterien
WO2008045252A2 (en) * 2006-10-04 2008-04-17 The Board Of Trustees Of The Leland Stanford Junior University Engineered integrin binding peptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
D1 : WENTZEL ET AL: "Display of passenger proteins on the surface of Escherichia coli K-12 by the Enterohemorrhagic E. coli Intimin EaeA". Journal of Bacteriology, 2001, vol. 183, pages 7273-7284 *

Also Published As

Publication number Publication date
AU2016210712B2 (en) 2017-10-26
JP2014504270A (ja) 2014-02-20
EP2638173A4 (en) 2014-03-26
EP2638173A1 (en) 2013-09-18
JP6170435B2 (ja) 2017-07-26
AU2011326164A1 (en) 2013-05-30
US11498952B2 (en) 2022-11-15
US20230227523A1 (en) 2023-07-20
WO2012064658A1 (en) 2012-05-18
CA2817197C (en) 2020-08-04
JP6535361B2 (ja) 2019-06-26
JP2017160222A (ja) 2017-09-14
DK2638173T3 (da) 2019-09-30
AU2016210712A1 (en) 2016-09-08
EP3604549A1 (en) 2020-02-05
US12240882B2 (en) 2025-03-04
CA2817197A1 (en) 2012-05-18
AU2018200587A1 (en) 2018-02-15
EP2638173B1 (en) 2019-06-19
US10844106B2 (en) 2020-11-24
US20140073518A1 (en) 2014-03-13
US20210206824A1 (en) 2021-07-08
AU2018200587B2 (en) 2019-12-12

Similar Documents

Publication Publication Date Title
US12240882B2 (en) Fusion proteins comprising an engineered knottin peptide and uses thereof
JP6486908B2 (ja) 肝細胞増殖因子に結合する設計アンキリン反復タンパク質
KR102717638B1 (ko) 뉴레귤린-4 화합물 및 사용 방법
US20130280162A1 (en) uPAR-ANTAGONISTS AND USES THEREOF
TWI356097B (en) Ccn1 compositions and methods
KR101263424B1 (ko) 세포투과성 엔도스타틴 재조합 단백질, 이를 코딩하는 폴리뉴클레오티드 및 이를 유효성분으로 함유하는 항암 조성물
WO2018109771A1 (en) Fusion proteins for treatment of cancer
US20230103583A1 (en) Method of enhancing aqueous humor outflow and reducing intraocular pressure
WO2021173177A1 (en) Chimeric fusions between c4-binding protein c-terminal segment and angiopoietin-1 fibrinogen-like domain as angiopoietin mimetics and tie2 agonists to treat vascular diseases
HK1190633A (zh) Upar拮抗剂及其应用

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired